17 April 2014 - Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) stated on Wednesday that it has introduced its US Food & Drug Administration (USFDA) approved Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg in the US market.

The company added that Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg is the therapeutic equivalent generic version of LUNESTA (eszopiclone) tablets C-IV in the US market.

According to IMS Health, the LUNESTA (eszopiclone) tablets C-IV brand and generic combined had US sales of about USD887m MAT for the most recent 12 months ending January 2014.

In conjunction, Dr Reddy's Eszopiclone Tablets (C-IV) 1 mg is available in bottle counts of 30 and the Eszopiclone Tablets (C-IV) 2 mg and 3 mg are available in bottle counts of 100.